Your session is about to expire
← Back to Search
VX15/2503 + Immunotherapy for Skin Cancer
Study Summary
This trial is testing VX15/2503 with or without ipilimumab and/or nivolumab to see if it can treat stage IIIB-D melanoma. Monoclonal antibodies may stop tumor cells from growing and spreading.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I have or had immune-related lung, gut, liver, hormone glands, kidney, or skin conditions.My kidney function, measured by creatinine levels or clearance, is within the required range.My cancer can be removed with surgery, and I am scheduled for a surgery evaluation.My melanoma is at stage IIIB, IIIC, or IIID.Your bilirubin levels in your blood should not be higher than 1.5 times the normal limit.My blood clotting time is normal or near normal, and if I'm on blood thinners, it's only low molecular weight heparin.Your blood platelet count is at least 100,000 per microliter.You have enough infection-fighting white blood cells in your body.I have been cancer-free for over 5 years, or I had non-melanoma skin cancer/in situ carcinoma that was completely removed.I am willing and able to follow the study's schedule and procedures.I haven't taken high-dose steroids or immunosuppressants in the last 14 days.I have not had serious infections needing treatment in the last week.My hemoglobin level is at least 9.0g/dL, even if I needed a blood transfusion.I agree to use two forms of birth control or practice complete abstinence while on the study and for 5 months after.I agree to use two forms of birth control or practice complete abstinence while on the study and for 7 months after.I haven't taken any experimental drugs recently.I do not have any major health issues that could interfere with the study.I am on long-term immunosuppressants like cyclosporine.I cannot have surgery because of other health issues.I haven't had immunotherapy with CTLA-4, PD-1, or VX15/2503 but may have had interferon over a year ago.My cancer is growing quickly.I am not pregnant or breastfeeding.Your levels of AST and ALT in the blood should be less than 2.5 times the normal limit.I haven't received vaccines other than for cancer within 4 weeks before or after getting ipilimumab.I have had an organ or bone marrow transplant from another person.I have a bleeding disorder or a condition affecting blood clotting.I am of childbearing age and have a negative pregnancy test.You have had serious allergic reactions to other types of antibodies in the past.Your albumin levels in your blood are higher than 3.0 grams per deciliter.
- Group 1: A (VX15/2503, nivolumab, surgery)
- Group 2: B (VX15/2503, ipilimumab, surgery)
- Group 3: C (VX15/2503, nivolumab, ipilimumab, surgery)
- Group 4: D (nivolumab, surgery)
- Group 5: E (surgery)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other experiments which have been performed utilizing VX15/2503?
"Currently, 768 trials are being conducted to investigate the effects of VX15/2503. Of these active research projects, 86 have reached Phase 3. Most studies for this promising medication occur in Pittsburgh, Pennsylvania; however there are 42810 different centres running related clinical trials worldwide."
To what extent is this experiment impacting the lives of participants?
"Affirmative. The clinical trial, which was initially posted on December 13th 2018 and most recently updated on February 11th 2022, is actively enrolling participants according to information available at clinicaltrials.gov. They require 42 patients from 1 centre for participation in the study."
What potential hazards are associated with VX15/2503 treatment?
"As a Phase 1 trial, VX15/2503 has minimal evidence behind its safety and efficacy. Consequently, it was assigned a score of one on the scale."
Is there an opportunity for new participants in this experimentation?
"Affirmative. According to the information available online, this clinical study commenced on December 13th 2018 and has been recently edited as of February 11th 2022. Currently it is enrolling 42 participants from one site."
What is the primary purpose of VX15/2503?
"VX15/2503 has proven effective in treating prior anti-angiogenic therapy, malignant tumours, and non-operable melanomas."
Share this study with friends
Copy Link
Messenger